Angstrom Pharmaceuticals, Inc.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
 
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 7248
 
 
 
G01N INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 1205

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

  • No Recent Publications to Display

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
8697629 Modulation of intracellular signalingMar 04, 11Apr 15, 14[A61K, C07K]
8313914 Compositions and methods for modulation of cell migrationMar 05, 10Nov 20, 12[A61K, G01N]
8110543 Anti-invasive and anti-angiogenic compositionsAug 30, 10Feb 07, 12[A61K]
7807621 Anti-invasive and anti-angiogenic compositionsNov 15, 06Oct 05, 10[A61K]
6936587 Anti-invasive and anti-angiogenic compositionsSep 03, 03Aug 30, 05[A61K]
6696416 Anti-invasive and anti-angiogenic compositionsNov 10, 99Feb 24, 04[A61K]
5994309 Anti-invasive and anti-angiogenic compositions and methodsJul 25, 97Nov 30, 99[A61K]
5942492 Cyclic peptides that bind to urokinase-type plasminogen activator receptorNov 12, 96Aug 24, 99[A61K]

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
6896870 Diagnostic probes and therapeutics targeting uPA and uPARExpiredSep 27, 00May 24, 05[A61K, A61M]
2004/0204,348 Cyclic peptide ligands that target urokinase plasminogen activator receptorAbandonedDec 22, 03Oct 14, 04[A61K, C07K]
6514710 Method of using cyclic peptides to inhibit binding to urokinase-type plasminogen activator receptorExpiredApr 05, 99Feb 04, 03[A61K, G01N]
6277818 Cyclic peptide ligands that target urokinase plasminogen activator receptorExpiredOct 29, 98Aug 21, 01[A61K, C07K]

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.